Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Membrane interactions of the globular domain and the hypervariable region of KRAS4b define its unique diffusion behavior.

Goswami D, Chen, Yang Y, Gudla PR, Columbus J, Worthy K, Rigby M, Wheeler M, Mukhopadhyay S, Powell K, Burgan W, Wall V, Esposito D, Simanshu D, Lightstone FC, Nissley DV, McCormick F, Turbyville T.

Elife. 2020 Jan 20;9. pii: e47654. doi: 10.7554/eLife.47654. [Epub ahead of print]

2.

Undermining glutaminolysis bolsters chemotherapy while NRF2 promotes chemoresistance in KRAS-driven pancreatic cancers.

Mukhopadhyay S, Goswami D, Adiseshaiah PP, Burgan W, Yi M, Guerin TM, Kozlov SV, Nissley DV, McCormick F.

Cancer Res. 2020 Jan 7. pii: canres.1363.2019. doi: 10.1158/0008-5472.CAN-19-1363. [Epub ahead of print]

PMID:
31911550
3.

Differential Effector Engagement by Oncogenic KRAS.

Yuan TL, Amzallag A, Bagni R, Yi M, Afghani S, Burgan W, Fer N, Strathern LA, Powell K, Smith B, Waters AM, Drubin D, Thomson T, Liao R, Greninger P, Stein GT, Murchie E, Cortez E, Egan RK, Procter L, Bess M, Cheng KT, Lee CS, Lee LC, Fellmann C, Stephens R, Luo J, Lowe SW, Benes CH, McCormick F.

Cell Rep. 2018 Feb 13;22(7):1889-1902. doi: 10.1016/j.celrep.2018.01.051.

4.

A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy.

Gillet JP, Andersen JB, Madigan JP, Varma S, Bagni RK, Powell K, Burgan WE, Wu CP, Calcagno AM, Ambudkar SV, Thorgeirsson SS, Gottesman MM.

Mol Pharmacol. 2016 Feb;89(2):263-72. doi: 10.1124/mol.115.101360. Epub 2015 Dec 14.

5.

Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma.

Shankavaram UT, Bredel M, Burgan WE, Carter D, Tofilon P, Camphausen K.

J Cell Mol Med. 2012 Mar;16(3):545-54. doi: 10.1111/j.1582-4934.2011.01345.x.

6.

Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102.

Buchanan IM, Scott T, Tandle AT, Burgan WE, Burgess TL, Tofilon PJ, Camphausen K.

J Cell Mol Med. 2011 Sep;15(9):1999-2006. doi: 10.1111/j.1582-4934.2010.01122.x. Epub 2010 Jul 12.

7.

Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts.

Baschnagel A, Russo A, Burgan WE, Carter D, Beam K, Palmieri D, Steeg PS, Tofilon P, Camphausen K.

Mol Cancer Ther. 2009 Jun;8(6):1589-95. doi: 10.1158/1535-7163.MCT-09-0038. Epub 2009 Jun 9.

8.

In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase.

Chung EJ, Brown AP, Asano H, Mandler M, Burgan WE, Carter D, Camphausen K, Citrin D.

Clin Cancer Res. 2009 May 1;15(9):3050-7. doi: 10.1158/1078-0432.CCR-08-2954. Epub 2009 Apr 14.

9.

In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.

Russo AL, Kwon HC, Burgan WE, Carter D, Beam K, Weizheng X, Zhang J, Slusher BS, Chakravarti A, Tofilon PJ, Camphausen K.

Clin Cancer Res. 2009 Jan 15;15(2):607-12. doi: 10.1158/1078-0432.CCR-08-2079.

10.

Postradiation sensitization of the histone deacetylase inhibitor valproic acid.

Chinnaiyan P, Cerna D, Burgan WE, Beam K, Williams ES, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2008 Sep 1;14(17):5410-5. doi: 10.1158/1078-0432.CCR-08-0643.

11.

In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide.

Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, Tofilon PJ, Camphausen K.

Clin Cancer Res. 2008 Feb 1;14(3):931-8. doi: 10.1158/1078-0432.CCR-07-1856.

12.

Inhibition of hsp90 compromises the DNA damage response to radiation.

Dote H, Burgan WE, Camphausen K, Tofilon PJ.

Cancer Res. 2006 Sep 15;66(18):9211-20.

13.

Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells.

de la Peña L, Burgan WE, Carter DJ, Hollingshead MG, Satyamitra M, Camphausen K, Tofilon PJ.

Mol Cancer Ther. 2006 Jun;5(6):1504-10.

14.

In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone).

Barker CA, Burgan WE, Carter DJ, Cerna D, Gius D, Hollingshead MG, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2006 May 1;12(9):2912-8.

15.

ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition.

Dote H, Cerna D, Burgan WE, Camphausen K, Tofilon PJ.

Cancer Res. 2005 Aug 1;65(15):6967-75.

16.

Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine.

Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, Hollingshead MG, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2005 Jun 15;11(12):4571-9.

17.

Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.

Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, Oswald KA, Hollingshead MG, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2004 Dec 1;10(23):8077-84.

18.

Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid.

Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, Fine H, Tofilon PJ.

Int J Cancer. 2005 Apr 10;114(3):380-6.

19.

Transcriptional signature of flavopiridol-induced tumor cell death.

Lü X, Burgan WE, Cerra MA, Chuang EY, Tsai MH, Tofilon PJ, Camphausen K.

Mol Cancer Ther. 2004 Jul;3(7):861-72.

20.

Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci.

Camphausen K, Brady KJ, Burgan WE, Cerra MA, Russell JS, Bull EE, Tofilon PJ.

Mol Cancer Ther. 2004 Apr;3(4):409-16.

21.

Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.

Camphausen K, Burgan W, Cerra M, Oswald KA, Trepel JB, Lee MJ, Tofilon PJ.

Cancer Res. 2004 Jan 1;64(1):316-21.

22.

Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity.

Russell JS, Brady K, Burgan WE, Cerra MA, Oswald KA, Camphausen K, Tofilon PJ.

Cancer Res. 2003 Nov 1;63(21):7377-83.

23.

Supplemental Content

Loading ...
Support Center